Clinical Trial

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

Study acronym: PNOC044
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed or progressive after standard upfront therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-14.
Trial Details
NCT Number NCT07346157
Lead Sponsor Sabine Mueller, MD, PhD
Conditions Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
Enrollment 69 participants
Start Date 2026-07-30
Primary Completion 2031-03-31 (estimated)
Study Completion 2031-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-01